Pipelines and Patients Drive Finished Dosage Opportunities

April 22, 2019

Efforts to ease patient burden with multi-API products and the increasing number of candidate products with low bioavailability are creating opportunities for contract manufacturing and development organizations (CDMOs) to create value with innovative, but complex, finished dosage formulations. Providing patients with solutions that allow them to dose less frequently and reduce complexity are a major selling point, CDMOs say. The emergence of smaller-volume products is creating practical challenges, however, for process design and scale-up.

Spotlight

Velesco Pharmaceutical Services

Velesco applies nimblocity to your early stage drug development projects, with our proven formulation of expertise, flexibility, dedication, and velocity to clinic.

OTHER WHITEPAPERS
news image

Market Access Trends in the US, Europe, and Emerging Markets

whitePaper | November 14, 2022

Rising drug spending and increased desire for expenditure controls are consistent themes across the US, Europe, and emerging markets.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomes in Diabetes

whitePaper | July 21, 2022

The growing costs of the diabetes epidemic in the U.S. are staggering. Over 37 million Americans around 11% of the population now have diabetes, and according to a recent study, over 60 million Americans are expected to have the disease by 2060.

Read More
news image

Manufacturing High-Quality Capsule Products for Pharmaceutical and Nutraceutical Applications

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.

Read More
news image

How Cellular is Enabling the Digital Supply Chain

whitePaper | January 12, 2020

Supply chains grow more and more complex every day. In response, manufacturers and shippers have been eagerly exploring digital tools that provide actionable insight into the location and condition of in-transit goods. Although there are many technology options when it comes to building a digital supply chain, one type of solution stands out as the most reliable and cost-effective: cellular.

Read More

Spotlight

Velesco Pharmaceutical Services

Velesco applies nimblocity to your early stage drug development projects, with our proven formulation of expertise, flexibility, dedication, and velocity to clinic.

Events